Kymera Therapeutics, Inc. (KYMR)
NASDAQ
Market Cap
$1.83B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
66 of 809
Rank in Industry
52 of 445
Largest Insider Buys in Sector
KYMR Stock Price History Chart
KYMR Stock Performance
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Insider Activity of Kymera Therapeutics, Inc.
Over the last 12 months, insiders at Kymera Therapeutics, Inc. have bought $5.3M and sold $38.81M worth of Kymera Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Kymera Therapeutics, Inc. have bought $25.1M and sold $63.01M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BVF PARTNERS L P/IL (director) — $100.73M.
The last purchase of 197,699 shares for transaction amount of $2.78M was made by BVF PARTNERS L P/IL (director) on 2023‑11‑03.
List of Insider Buy and Sell Transactions, Kymera Therapeutics, Inc.
| 2024-06-13 | Sale | Booth Bruce | director | 10,200 0.0168% | $34.98 | $356,796 | -9.81% | |
| 2024-06-12 | Sale | Booth Bruce | director | 16,740 0.028% | $35.45 | $593,378 | -8.57% | |
| 2024-06-07 | Sale | Horobin Joanna | director | 8,500 0.0139% | $32.99 | $280,400 | -2.94% | |
| 2024-05-23 | Sale | Chadwick Jeremy G | Chief Operating Officer | 2,575 0.0043% | $34.99 | $90,105 | -5.17% | |
| 2024-03-15 | Sale | Booth Bruce | director | 71,764 0.1171% | $40.46 | $2.9M | -13.23% | |
| 2024-03-14 | Sale | Booth Bruce | director | 55,779 0.0861% | $39.98 | $2.23M | -10.78% | |
| 2024-03-13 | Sale | Booth Bruce | director | 139,255 0.2271% | $42.23 | $5.88M | -16.65% | |
| 2024-03-13 | Sale | Atlas Venture Fund X, L.P. | 10 percent owner | 139,255 0.2271% | $42.23 | $5.88M | -16.65% | |
| 2024-03-12 | Sale | Booth Bruce | director | 162,918 0.2674% | $41.98 | $6.84M | -15.72% | |
| 2024-03-12 | Sale | Atlas Venture Fund X, L.P. | 10 percent owner | 162,918 0.2674% | $41.98 | $6.84M | -15.72% | |
| 2024-03-11 | Sale | Booth Bruce | director | 51,184 0.0849% | $42.85 | $2.19M | -16.61% | |
| 2024-03-11 | Sale | Atlas Venture Fund X, L.P. | 10 percent owner | 51,184 0.0849% | $42.85 | $2.19M | -16.61% | |
| 2024-03-04 | Sale | Jacobs Bruce N. | Chief Financial Officer | 3,934 0.0064% | $41.86 | $164,664 | -16.33% | |
| 2024-03-04 | Sale | Gollob Jared | Chief Medical Officer | 3,344 0.0054% | $41.86 | $139,967 | -16.33% | |
| 2024-02-27 | Sale | Gollob Jared | Chief Medical Officer | 400 0.0007% | $45.00 | $18,000 | -17.78% | |
| 2024-02-21 | Sale | Albers Jeffrey W. | director | 4,385 0.0075% | $39.05 | $171,227 | -6.59% | |
| 2024-02-20 | Sale | Albers Jeffrey W. | director | 615 0.0011% | $39.07 | $24,031 | -4.73% | |
| 2024-02-09 | Sale | Gollob Jared | Chief Medical Officer | 46,137 0.0835% | $35.50 | $1.64M | -2.45% | |
| 2024-01-23 | Sale | Albers Jeffrey W. | director | 10,000 0.0163% | $30.05 | $300,470 | +15.48% | |
| 2024-01-04 | Sale | Chiniara Ellen | Chief Legal Officer | 3,295 0.005% | $22.58 | $74,416 | +29.72% |
Insider Historical Profitability
8.43%
| BVF PARTNERS L P/IL | director | 2656191 4.4738% | $29.89 | 8 | 0 | <0.0001% |
| Booth Bruce | director | 802022 1.4993% | $29.89 | 0 | 18 | |
| Atlas Venture Fund X, L.P. | director | 828830 1.4993% | $29.89 | 0 | 12 | |
| Jacobs Bruce N. | Chief Financial Officer | 142351 0.1761% | $29.89 | 0 | 10 | |
| Gollob Jared | Chief Medical Officer | 95740 0.1258% | $29.89 | 0 | 14 | |
| Chadwick Jeremy G | Chief Operating Officer | 44183 0.072% | $29.89 | 0 | 1 | |
| Chiniara Ellen | Chief Legal Officer | 34205 0.0576% | $29.89 | 0 | 1 | |
| Horobin Joanna | director | 0 0% | $29.89 | 0 | 1 | |
| Albers Jeffrey W. | director | 0 0% | $29.89 | 0 | 3 | |
| Mainolfi Nello | Chief Executive Officer | 472199 0.7953% | $29.89 | 0 | 26 | |
| LAMPERT MARK N | 257754 0.4341% | $29.89 | 4 | 0 | +55.88% | |
| Caughey Elaine | Chief Business Officer | 18986 0.032% | $29.89 | 0 | 1 | |
| Chesworth Richard | Chief Scientific Officer | 0 0% | $29.89 | 0 | 2 | |
| ATLAS VENTURE ASSOCIATES X, L.P. | 10 percent owner | 0 0% | $29.89 | 0 | 2 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| T. Rowe Price | $254.55M | 10.32 | 6.33M | +18.67% | +$40.05M | 0.03 | |
| Baker Bros Advisors LP | $241.04M | 9.77 | 6M | 0% | +$0 | 3.03 | |
| Atlas Venture Life Science Advisors Llc | $216.17M | 8.76 | 5.38M | -8.21% | -$19.33M | 20.63 | |
| Bvf Inc Il | $207.5M | 8.41 | 5.16M | 0% | +$0 | 1.52 | |
| The Vanguard Group | $191.64M | 7.77 | 4.77M | +19.25% | +$30.93M | <0.01 | |
| Fidelity Investments | $175.45M | 7.11 | 4.36M | +716.39% | +$153.96M | 0.01 | |
| Wellington Management Company | $172.61M | 7 | 4.29M | -10.84% | -$20.98M | 0.03 | |
| Avoro Capital Advisors Llc | $156.33M | 6.34 | 3.89M | +3.02% | +$4.58M | 1.87 | |
| BlackRock | $146.96M | 5.96 | 3.66M | +2.5% | +$3.58M | <0.01 | |
| Artal Group S A | $121.69M | 4.93 | 3.03M | +19.61% | +$19.96M | 0.65 | |
| State Street | $107.44M | 4.36 | 2.67M | +41.08% | +$31.29M | 0.01 | |
| Redmile Group | $69.71M | 2.83 | 1.73M | -4.93% | -$3.61M | 2.58 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $61.19M | 2.48 | 1.52M | 0% | +$0 | 1.56 | |
| Deep Track Capital Lp | $50.74M | 2.06 | 1.26M | New | +$50.74M | 0.23 | |
| Geode Capital Management | $38.83M | 1.57 | 965,700 | +9.67% | +$3.42M | <0.01 | |
| Marshall Wace | $23.03M | 0.93 | 572,926 | New | +$23.03M | 0.03 | |
| Morgan Stanley | $22M | 0.89 | 547,140 | +23.99% | +$4.26M | <0.01 | |
| Woodline Partners LP | $20.14M | 0.82 | 500,930 | +397.2% | +$16.09M | 0.19 | |
| JPMorgan Chase | $18.33M | 0.74 | 455,936 | -10.99% | -$2.26M | <0.01 | |
| Goldman Sachs | $18.11M | 0.73 | 450,518 | -33.22% | -$9.01M | <0.01 | |
| JENNISON ASSOCIATES LLC | $17.12M | 0.69 | 425,920 | New | +$17.12M | 0.01 | |
| Deer Management Co Llc | $16.72M | 0.68 | 415,895 | -32.47% | -$8.04M | 3.28 | |
| Massachusetts Financial Services Co Ma | $15.88M | 0.64 | 395,139 | -14.6% | -$2.71M | 0.01 | |
| Spyglass Capital Management LLC | $15.63M | 0.63 | 388,743 | -55.89% | -$19.8M | 11.71 | |
| Schonfeld Group | $15.29M | 0.62 | 380,442 | -13.07% | -$2.3M | 0.11 | |
| Northern Trust | $14.99M | 0.61 | 372,786 | +3.96% | +$571,121.43 | <0.01 | |
| Charles Schwab | $14.24M | 0.58 | 354,106 | +15.46% | +$1.91M | <0.01 | |
| Dimensional Fund Advisors | $14.04M | 0.57 | 349,209 | -34.57% | -$7.42M | <0.01 | |
| Candriam S C A | $13.2M | 0.54 | 328,302 | -4.37% | -$602,999.98 | 0.09 | |
| Barclays | $12.86M | 0.52 | 319,901 | -16.21% | -$2.49M | 0.01 | |
| UBS | $11.93M | 0.48 | 296,680 | -1.26% | -$152,076.60 | <0.01 | |
| Voloridge Investment Management, LLC | $10.75M | 0.44 | 267,514 | +10.63% | +$1.03M | 0.02 | |
| Citadel Advisors LLC | $10.51M | 0.43 | 261,381 | -29.63% | -$4.42M | 0.01 | |
| Credit Suisse | $9.15M | 0.37 | 227,586 | +38.64% | +$2.55M | 0.01 | |
| Citigroup | $8.88M | 0.36 | 220,911 | +148.41% | +$5.31M | 0.01 | |
| Td Asset Management Inc | $8.8M | 0.36 | 218,804 | +17.33% | +$1.3M | 0.01 | |
| Rafferty Asset Management Llc | $8.48M | 0.34 | 210,861 | +75.44% | +$3.65M | 0.03 | |
| Two Sigma Advisers LP | $8.41M | 0.34 | 209,100 | +22.35% | +$1.54M | 0.01 | |
| Ubs Asset Management Americas Inc | $7.23M | 0.29 | 179,938 | +1.95% | +$138,207.59 | <0.01 | |
| Trexquant Investment LP | $6.52M | 0.26 | 162,115 | -20.36% | -$1.67M | 0.09 | |
| Bank of America | $6.52M | 0.26 | 162,291 | +441.01% | +$5.32M | <0.01 | |
| Great Lakes Advisors® | $6.29M | 0.26 | 156,377 | New | +$6.29M | 0.06 | |
| Gilder Gagnon Howe & Co. LLC | $5.35M | 0.22 | 132,989 | New | +$5.35M | 0.07 | |
| BNY Mellon | $5.26M | 0.21 | 130,894 | -2.02% | -$108,419.40 | <0.01 | |
| Two Sigma | $5.14M | 0.21 | 127,746 | -3.63% | -$193,683.59 | 0.01 | |
| Neuberger Berman | $5.03M | 0.2 | 125,179 | +3.39% | +$164,820.01 | <0.01 | |
| Schroder Investment Management Group | $4.86M | 0.2 | 120,847 | -34.78% | -$2.59M | 0.01 | |
| The Manufacturers Life Insurance Company | $4.61M | 0.19 | 114,757 | +14.67% | +$590,296.75 | <0.01 | |
| Invesco | $4.56M | 0.19 | 113,367 | +303.6% | +$3.43M | <0.01 | |
| AXA | $4.39M | 0.18 | 109,217 | New | +$4.39M | 0.01 |